English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
Thursday, 12th December at 9:15 am
Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery
Factors supporting the go-ahead for the 212-person registration study in the target population include:
Multikine led to significant rates of tumor regression
Pre-surgical tumor regressions were confirmed at surgery and forecast survival benefit
Target population is likely to show significant survival prolongation in the confirmatory study
Confirmatory study target population selection is based on:
Strong statistical significance in a large subgroup of 114 patients
Subgroup analysis was pre-defined in the statistical analysis plan (SAP)
Strong biological rationale for the results based on Multikine's mechanism of action (MOA)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
12K Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    8808
    Followers
    53
    Following
    103K
    Visitors
    Follow